Holen Sie sich die Stockscreener-App
41.79
7.15%
2.79
Vorhandelsmarkt:
42.20
0.41
+0.98%
Schlusskurs vom Vortag:
$39.00
Offen:
$38.37
24-Stunden-Volumen:
1.55M
Relative Volume:
1.44
Marktkapitalisierung:
$2.58B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-229.97M
KGV:
-9.666
EPS:
-4.3234
Netto-Cashflow:
$-136.51M
1W Leistung:
+9.63%
1M Leistung:
+68.10%
6M Leistung:
+193.68%
1J Leistung:
+1,817%
1-Tages-Spanne:
$38.37
$42.95
1-Wochen-Bereich:
$38.22
$44.30
52-Wochen-Spanne:
$1.92
$45.60
Kodiak Sciences Inc Stock (KOD) Company Profile
Firmenname
Kodiak Sciences Inc
Sektor
Branche
Telefon
650-281-0850
Adresse
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
41.79 | 2.58B | 0 | -229.97M | -136.51M | -4.3234 |
VRTX
Vertex Pharmaceuticals Inc
|
431.86 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.27 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
765.43 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.52 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.03 | 35.19B | 606.42M | -1.28B | -997.58M | -6.403 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-11 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-25 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-09-22 | Eingeleitet | Jefferies | Buy |
| 2025-08-14 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-05 | Eingeleitet | H.C. Wainwright | Neutral |
| 2023-12-11 | Fortgesetzt | Goldman | Sell |
| 2023-11-17 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-07-25 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-24 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-07-24 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-15 | Eingeleitet | CapitalOne | Overweight |
| 2022-08-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-02-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2022-02-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-02-17 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-11-30 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-11-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-03 | Eingeleitet | Goldman | Buy |
| 2020-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-02-06 | Eingeleitet | SunTrust | Buy |
| 2020-01-08 | Eingeleitet | ROTH Capital | Buy |
| 2020-01-03 | Eingeleitet | Jefferies | Buy |
| 2019-12-24 | Eingeleitet | JP Morgan | Overweight |
| 2019-10-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2018-10-29 | Eingeleitet | Barclays | Overweight |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Buy |
| 2018-10-29 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Kodiak Sciences Inc Aktie (KOD) Neueste Nachrichten
Kodiak Sciences Achieves Strong Gains with Positive GLOW2 Trial Results - timothysykes.com
Kodiak Sciences GLOW2 Win Puts Zenkuda And Funding Needs In Focus - finance.yahoo.com
Assessing Kodiak Sciences (KOD) Valuation After Recent Share Price Momentum And Conflicting Signals - finance.yahoo.com
Kodiak Q4 loss wider than expected, pipeline development in focus - MSN
Kodiak Sciences Insider Sold Shares Worth $1,197,488, According to a Recent SEC Filing - marketscreener.com
Kodiak climbs on late-stage trial win for diabetic retinopathy therapy - MSN
Kodiak Sciences | 10-K: FY2025 Annual Report - Moomoo
Kodiak Sciences Faces Going Concern Warning As Valuation Gap Persists - Sahm
Lifesci Capital Trims Earnings Outlook for Kodiak Sciences - National Today
Q1 EPS Estimates for Kodiak Sciences Decreased by Analyst - MarketBeat
Lifesci Capital Forecasts Lower Earnings for Kodiak Sciences - MarketBeat
Kodiak Sciences CFO Borgeson sells $1.2m in shares By Investing.com - Investing.com India
Kodiak Sciences CFO Borgeson sells $1.2m in shares - Investing.com
Kodiak Sciences (KOD) CFO exercises 30K options and sells 30K shares under 10b5-1 plan - Stock Titan
Kodiak Sciences Inc. (KOD) stock price, news, quote and history - Yahoo Finance UK
[144] Kodiak Sciences Inc. SEC Filing - Stock Titan
Point72 reports 609,806 shares in Kodiak (KOD) — 1.0% stake - Stock Titan
Kodiak Sciences Inc. (KOD) options chain - Yahoo Finance Singapore
Kodiak Sciences (KOD) Sees Decline as Stock Falls 8.7% - gurufocus.com
Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation - Moomoo
Kodiak Sciences Inc. (KOD) Latest Stock News & Headlines - Yahoo! Finance Canada
Fed Meeting: Can Kodiak Sciences Inc lead its sector in growthQuarterly Market Summary & Breakout Confirmation Trade Signals - baoquankhu1.vn
Kodiak Sciences 2025 Financial Update - AlphaStreet
Kodiak Sciences (KOD) Reports Positive Developments in Q4 Results - GuruFocus
Kodiak Sciences (KOD) Shares Surge Over 10% - GuruFocus
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus - The Globe and Mail
Kodiak Sciences Stock Soars Amid Positive Phase 3 Findings - StocksToTrade
Kodiak Sciences Stock (KOD) Rallies as Analysts Weigh In After Earnings - TipRanks
Why Kodiak Sciences Stock Is Suddenly Surging - TipRanks
Kodiak Sciences (NASDAQ:KOD) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Kodiak Sciences Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Kodiak Sciences (NASDAQ: KOD) outlines retinal pipeline and going-concern risk - stocktitan.net
Phase 3 win and 2027 cash runway for Kodiak Sciences (NASDAQ: KOD) - stocktitan.net
Kodiak Sciences Q4 net loss widens on higher R&D spending - TradingView
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - Bitget
BRIEF-Kodiak Sciences Q4 Net Income USD -56.736 Million - TradingView
Kodiak Sciences (NASDAQ:KOD) Trading 8.3% HigherHere's Why - MarketBeat
Kodiak Sciences stock is surging Friday: What's driving the action? - MSN
Kodiak Sciences (KOD) climbs 75% on stellar clinical results - msn.com
Kodiak reports positive phase 3 data on tarcocimab for DR - Eyes On Eyecare
Kodiak Sciences stock hits 52-week highhere's why - MSN
MACD Signal: Can Kodiak Sciences Inc grow without dilution2026 Risk Factors & Real-Time Volume Spike Alerts - baoquankhu1.vn
Kodiak Sciences Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Kodiak Sciences (NASDAQ:KOD) Trading Down 7.8%Time to Sell? - MarketBeat
Kodiak Sciences: Road To $120 - Forbes
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing - AOL.com
Kodiak Sciences (KOD) Is Up 66.3% After Strong Zenkuda GLOW2 Phase 3 DataHas The Bull Case Changed? - Yahoo Finance
Kodiak Sciences (KOD) Is Up 66.3% After Zenkuda’s Phase 3 Win in Diabetic Retinopathy - simplywall.st
Kodiak Sciences (KOD) CEO exercises 300,000 stock options into common shares - Stock Titan
Finanzdaten der Kodiak Sciences Inc-Aktie (KOD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
2.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):